Construction method and application of ST cell strain for stable overexpression of RPSA
Through liposome transfection and puromycin screening technology, ST cell lines that are stably overexpressing RPSA were constructed, solving the cumbersome problem of cell line screening in the existing technology, and achieving efficient production of PRV vaccines.
Patent Information
- Application Number
- CN202310652884.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-05
- Publication Date
- 2024-12-06
AI Technical Summary
When the prior art builds a stable overexpression of RPSA cell lines, the screening monoclonal process is cumbersome and it is difficult to efficiently identify positive clones, which affects the efficient production of PRV vaccines.
ST cells were transfected with pIRES-RPSA-Flag recombinant plasmid expressing porcine RPSA protein by liposome transfection, and ST cell lines that were stably overexpressed RPSA were established by puromycin screening, and puromycin concentration was optimized for monoclonal screening. , add Flag tags for easy identification.
An efficient and stable RPSA overexpressing cell line was constructed, which promoted PRV virus replication, increased vaccine yield, and provided a new cellular matrix for PRV vaccine production.
Smart Images

Figure CN119082039A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a method for constructing a cell line and application thereof, and more specifically, to a method for constructing a ST cell line stably overexpressing RPSA and application thereof, belonging to the field of biotechnology. Background Art
[0002] Pseudorabies (PR) is an infectious disease of livestock and wild animals caused by pseudorabies virus (PRV), with fever and encephalomyelitis as the main symptoms. Pseudorabies causes miscarriage, stillbirth and mummification in pregnant sows; lactating piglets will have fever, neurological failure and death, with a mortality rate close to 100%; adult pigs are infected without obvious symptoms, but they carry the virus for a long time and become the main source of infection in pig farms. Therefore, it brings great challenges to the prevention and control of PRV in my country.
[0003] Reasonable vaccination can greatly reduce the harm of PRV. European and American countries such as the United States, Canada, New Zealand, Germany and Denmark have successively achieved the purification and eradication of PRV through strict vaccination programs. High titer antigen is the primary condition for the preparation of high-quality vaccines. PRV has tropism for a variety of cells. Currently, BHK-21 cells, PK-15 cells, Vero cells and ST cells are commonly used to produce PRV vaccines. At present, fully suspended ST cells have become one of the main matrices for the production of PRV vaccines in my country.
[0004] Host ribosomal protein SA (RPSA) is a component of ribosomal subunits and is widely expressed in cells. RPSA is a receptor for dengue virus, classical swine fever virus, and Venezuelan equine encephalitis virus; RPSA inhibits the MAPK pathway and thus inhibits the replication of foot-and-mouth disease virus; RPSA activates the ERK pathway to promote the replication of Seneca virus. RPSA is widely used in tumor research, and it activates the ERK1 / 2 signaling pathway to regulate the survival of tumor cells. PRV infection can regulate the activation of the ERK1 / 2 signaling pathway to guide its own replication. Similarly, the construction of stable cell lines requires tedious and lengthy steps. How to identify positive clones in the process of screening single clones is a problem worthy of attention. Summary of the invention
[0005] The purpose of the present invention is to provide a method for constructing a ST cell line that stably overexpresses RPSA and its application, which has the technical characteristics of being able to construct an efficient and stable RPSA overexpressing cell line and providing a new cell matrix for the efficient production of PRV vaccine.
[0006] In order to achieve the above object, the present invention is implemented by the following technical solutions:
[0007] A method for constructing a ST cell line that stably overexpresses RPSA, characterized in that the construction method comprises the following steps: transfecting ST cells with a pIRES-RPSA-Flag recombinant plasmid expressing porcine RPSA protein based on a liposome transfection method, and establishing a ST cell line that stably overexpresses RPSA after screening single clones with puromycin.
[0008] Preferably, the RPSA gene is from a pig source, and the RPSA sequence is shown in NO.1.
[0009] Preferably, the carboxyl terminus of the RPSA sequence contains a Flag tag protein.
[0010] Preferably, the cell line used is ST cell.
[0011] Preferably, the vector used for the recombinant plasmid is pIRES.
[0012] Preferably, the RPSA sequence is amplified before the recombinant plasmid, and the forward primer and reverse primer sequences for amplifying the RPSA sequence are shown as No. 2 and No. 3, respectively.
[0013] The invention discloses an application of a ST cell line stably overexpressing RPSA, including application in producing pseudorabies vaccine.
[0014] Preferably, the constructed ST cell line stably overexpressing RPSA is used for amplification of PRV virus, which can increase the PRV virus titer and thus increase the vaccine yield.
[0015] Beneficial effects: The present invention can construct an efficient and stable RPSA overexpressing cell line; the ST cell line stably overexpressing RPSA can promote PRV virus replication and can be used for the proliferation and culture of PRV virus, providing a new cell matrix for the efficient production of PRV vaccine. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 This is the enzyme digestion identification diagram of the recombinant plasmid pIRES-puro-RPSA-Flag of the present invention;
[0017] Figure 2 This is a graph showing the cell survival of wild-type ST cells incubated in different puromycin-containing media at different times;
[0018] Figure 3 This is a summary of Western blotting results of RPSA-Flag expression in ST cell lines that stably overexpress RPSA after three consecutive passages;
[0019] Figure 4 is the TCID of PRV in wild-type ST and ST cell lines stably overexpressing RPSA 50 Titration diagram.
[0020] in, Figure 1 In the assay, the marker is DL10000bp. DETAILED DESCRIPTION
[0021] The present invention will be further described below in conjunction with the accompanying drawings, but the present invention is not limited to the following embodiments.
[0022] A method for constructing a stably transfected ST cell line that stably overexpresses RPSA, the construction steps are as follows:
[0023] 1) Construction of pIRES-RPSA-Flag plasmid: amplify the RPSA-Flag gene and insert it into the pIRES plasmid, transform DH5α competent cells to obtain the recombinant plasmid, i.e., pIRES-RPSA-Flag;
[0024] 2) Selection of puromycin working concentration: Use a final concentration of 0-2.5 μg / mL puromycin to inoculate wild-type ST cells and observe cell death every day;
[0025] 3) Cell transfection and screening: The pIRES-RPSA-Flag plasmid was transfected into low-passage ST cells, and then puromycin at a final concentration of 1 μg / mL was added for screening for 3 consecutive days. Monoclones were screened by cloning rings, and Flag antibodies were used for identification after expansion culture.
[0026] 4) Virus titration: The same number of wild-type ST cells and RPSA stable overexpression cell lines were plated and inoculated with equal doses of PRV virus. After 48 hours, the cell supernatant was collected and titrated by TCID 50 The construction of ST cell lines with stable overexpression of RPSA for the amplification of PRV virus can increase the PRV titer and thus increase the vaccine production.
[0027] The present invention has the following innovative features:
[0028] 1) Adding a Flag tag to the carboxyl terminus of the target protein facilitates subsequent monoclonal identification.
[0029] 2) Use the pIRES-puro plasmid containing the puromycin resistance gene.
[0030] 3) The working concentration of puromycin was optimized, and good results were obtained by adding low concentration 1 μg / mL puromycin for continuous screening for 3 days.
[0031] 4) The present invention is applied to the construction of an efficient and stable RPSA overexpression cell line, providing a new cell matrix for the efficient production of PRV vaccine.
[0032] In summary, the purpose of the present invention is to increase the PRV virus titer by overexpressing RPSA in ST cells, and connecting a Flag tag to the carboxyl terminus of RPSA for monoclonal identification.
[0033] Technical route: Amplify the RPSA coding sequence and add a Flag tag at the carboxyl end to clone into the pIRES-puromycin vector to obtain the pIRES-puro-RPSA-Flag recombinant plasmid, transfect ST cells, use the appropriate concentration of puromycin for screening, and then select monoclonal cells. Finally, use Western blotting to identify the monoclonal cell line. The constructed ST cell line that stably overexpresses RPSA can be used for the amplification of PRV virus, which can increase the PRV virus titer and thus increase the vaccine production.
[0034] 1. Purpose of the experiment
[0035] An ST cell line that stably overexpresses RPSA was constructed and verified to be able to be used for the amplification of PRV virus, which can increase the PRV virus titer and thus increase vaccine production, providing a new cell matrix for the efficient production of PRV vaccine.
[0036] 2. Experimental Materials
[0037] The pIRES plasmid, swine-testicle (ST) cells, pseudorabies virus strain PRV-ZSTU and DH5α competent cells used in this experiment were stored in our laboratory; DMEM high-glucose medium and Opti-MEM reduced serum medium were purchased from Gibco; newborn calf serum (NCS) was purchased from AusgeneX; penicillin-streptomycin-amphotericin B antibiotics were purchased from Bio-Time; RNA extraction kit FastPure Cell / Tissue Total RNA Isolation Kit V2, reverse transcription kit HiScriptⅡQ RT SuperMixfor qPCR (+gDNAwiper), homologous recombination kit ClonExpress II One Step Cloning Kit and high-fidelity enzymes were purchased from Novozymes Biotech Co., Ltd. Restriction enzymes EcoRⅠ, NheⅠ and NdeⅠ; plasmid DNA mini kit was purchased from Axygen; endotoxin-free plasmid mini kit I was purchased from Omega Bio-Tek, and Lipofectamine LTX&Plus transfection reagent was purchased from Thermo Fisher Scientific; puromycin was purchased from Yisheng Biotechnology Co., Ltd.; anti-Flag monoclonal antibody was purchased from Sigma, anti-GAPDH monoclonal antibody was purchased from Proteintech, and horseradish peroxidase-labeled goat anti-mouse secondary antibodies were purchased from Beyotime.
[0038] 3. Test methods
[0039] 3.1 Construction of pIRES-RPSA-Flag recombinant plasmid
[0040] The ST cell RNA was extracted using a kit. After measuring the concentration, 1 μg of total RNA was reverse transcribed to obtain cDNA. The RPSA gene sequence was obtained from GenBank as shown in NO 1. The upstream primer ST-RPSA-F was designed to amplify the RPSA sequence as shown in NO 2. The downstream primer ST-RPSA-R was used to add the Flag tag sequence as shown in NO 3. According to the manufacturer's instructions, the RPSA-Flag gene fragment was amplified using a high-fidelity enzyme and then recovered by gel cutting. The pIRES-puro plasmid was digested with EcoR I and NheⅠ restriction endonucleases. The linearized plasmid was recovered after nucleic acid electrophoresis separation. The RPSA-Flag was cloned into the pIRES-puro plasmid using the homologous recombination method. The DH5α competent cells were transformed using the TSS method. The transformed DH5α was screened on Amp-resistant LB solid medium plates. The primers ST-RPSA-F and ST-RPSA-R were used for colony PCR to preliminarily screen and identify the successfully transformed strains. The correct single clone was expanded and cultured to extract the plasmid, and then it was identified by double restriction digestion with NheⅠ and EcoRⅠ, as shown in FIG. Figure 1 As shown, the sizes were basically consistent with the theoretical values of 1616 bp and 5999 bp. The correct plasmid identified by sequencing was finally named pIRES-puro-RPSA-Flag, and the plasmid was extracted using an endotoxin-free method for later use.
[0041] RPSA sequence NO 1:
[0042] Atgtccggagccctcgatgtcctgcaaatgaaagaggaggatgtcctcaagttccttgcagcaggaacccaccttggtggcaccaaccttgacttccaaatggaacagtacatctacaaaaggaaaagtgatggcatctacatcataaatctgaagagaacctgggagaaacttctgttggcggctcgtgccatcgttgccattgaaaacccagccgatgtcagtgtcatatcctccaggaatactggccagcgagctgtgctgaagtttgctgctgccactggagccactcctattgctggccgcttcactcctggaaccttcactaaccagatccaggcagccttccgggagccaagacttctggtggttactgatcccagggctgaccaccagcctctcacagaggcctcttatgttaacctgcctaccattgctctgtgtaacacagactcacctctgcgttatgtggacattgccatcccgtgcaacaacaagggagctcactcagtgggtctgatgtggtggatgctcgcccgggaagttctgcgcatgcgtggcaccatctcccgggaacacccatgggaagtcatgcctgacctctacttctacagagatcctgaagagattgaaaaggaagagcaggccgcagctgagaaggctgtgaccaaggaggaatttcagggtgaatggactgcgccagctcctgagttcactgccactcaacctgaggtggcagattggtccgaaggtgtgcaggtgccttctgtgcccatccagcaattccctactgaagattggagtgctcagcctaccactgaagattggtctgcagctcccactgcgcaggccactgaatgggtaggaacaaccactgagtggtcttaa
[0043] Forward primer ST-RPSA-F sequence NO 2:
[0044] ST-RPSA-F: CGGAATTCCGATGTCCGGAGCCCTCGATG
[0045] Downstream primer ST-RPSA-R adds Flag tag sequence NO 3:
[0046] ST-RPSA-R: ATGCATGCTCGACGGCTGAATTCTTACTTGTCATCGTCG TCCTTGTAATCAGACCACTCAGTGGTTGTTCC
[0047] 3.2 Selection of working concentration of puromycin
[0048] ST cells were inoculated into 12-well cell culture plates, and 1 mL of culture medium with final concentrations of 0, 0.5, 1, 1.5, 2, and 2.5 μg / mL puromycin was added for 12 h. Then, photographs were taken after 0, 24, 48, and 72 h to observe the cell status. Figure 2 According to the results, a puromycin concentration of 1 μg / mL, which caused all wild-type ST cells to die on the third day, was selected as the optimal screening concentration.
[0049] 3.3 Transfection of ST cells
[0050] ST cells were cultured in complete medium (DMEM medium containing 10% NCS + 1% triple antibody) in a 37°C 5% CO2 incubator. Cells with good growth status were transferred to a 12-well plate. When the confluence reached about 70%, 2 μg of pIRES-puro-RPSA-Flag plasmid was transfected to prepare transfection complex A: 2 μg of plasmid, 2 μL of Plus Reagent and Opti-mem to 150 μL. Transfection complex B: 4 μL of Lipofectamine LTX Reagent was added to Opti-mem to 150 μL. The complex A and B systems were prepared and allowed to stand at room temperature for 5 minutes, then the A solution was slowly added to the B solution and gently mixed and allowed to stand again for 10 minutes. After the transfected cells were replaced with 1.7 mL of Opti-MEM medium preheated to 37°C, 300 μL of the transfection complex A and B mixture was evenly added to the cell culture plate. After 12 hours, it was replaced with complete medium and continued to be cultured for 36 hours.
[0051] 3.4 Puromycin pressure screening and identification
[0052] 48 hours after transfection, the cells were rinsed with PBS once to remove dead cells, and then 2 mL of complete medium with a final concentration of 1 μg / mL puromycin was added for continuous screening for 3 days, during which new medium containing drugs was replaced every 1 day. After that, the cells were collected and divided into two parts, half of which was used to detect the expression of RPSA-Flag fusion protein by Western blotting using anti-Flag antibody, and the other half was plated with 100 cells / 10 cm culture dish, added with complete medium and cultured for about 14 days, and new medium was replaced every 5 days. Monoclonal cell clusters were selected using cloning rings and passaged to 96-well plates. After confluent, 24-well plates were used for expansion culture. After confluent again, half of the cells were taken for Western blotting detection. The cells were lysed on ice for 10 minutes with 100 μl protein lysis buffer, and the cells were repeatedly blown and collected in a 1.5 mL EP tube. The cells were centrifuged at 4°C and 12,000 rpm for 10 minutes. The supernatant was collected and added with denatured loading buffer in proportion, boiled at 100°C for 10 minutes, and anti-Flag antibody was used to detect RPSA-Flag expression. GAPDH was selected as an internal reference, and wild-type ST cells were used as a control. After verification, the cells were expanded and frozen, and monoclonal cells were subcultured three times for Western blotting to identify the Flag tag. The results showed that the two ST cell lines that stably overexpressed RPSA, ST-RPSA-1 and ST-RPSA-2, had the target band at about 43 kDa, while the control group had no band, indicating that the RPSA-Flag gene was successfully inserted into the ST cell genome and expressed as Figure 3 shown.
[0053] 3.5 Proliferation of PRV in RPSA Stably Transfected Cell Lines
[0054] The ST cell lines ST-RPSA-1, ST-RPSA-2 and wild-type ST cells that stably overexpress RPSA were inoculated into 24-well cell culture plates in the same number, 0.5 mL per well. PRV-ZSTU was infected at a dose of MOI = 0.01, and the virus was mixed with serum-free DMEM and added to the cell culture plate for incubation at 37°C for 1 hour. The cell culture plate was gently shaken every 20 minutes. After that, the culture medium was replaced with DMEM containing 2% NCS and continued to be cultured. The supernatant was collected at 24h and 48h after infection, and the virus TCID in the supernatant was determined. 50 ,like Figure 4 The results showed that compared with wild-type ST cells, the virus titer of ST cell lines stably overexpressing RPSA increased to a certain extent at 24h after infection, and the virus titer increased significantly by about 4 times at 48h.
[0055] This indicates that the ST cell line stably overexpressing RPSA can promote PRV virus replication and can be used for the proliferation and culture of PRV virus, so it can serve as a new good matrix for PRV vaccine production.
[0056] Finally, it should be noted that the present invention is not limited to the above embodiments, and there are many variations. All variations that can be directly derived or associated with the content disclosed by ordinary technicians in this field should be considered as the protection scope of the present invention.
Claims
1. A method for constructing a ST cell line stably overexpressing RPSA, characterized in that The construction method comprises the following steps: based on the liposome transfection method, a pIRES-RPSA-Flag recombinant plasmid expressing porcine RPSA protein is transfected into ST cells, and after the monoclonal clone is screened by puromycin, an ST cell line stably over-expressing RPSA is established.
2. The method for constructing a ST cell line stably overexpressing RPSA according to claim 1, wherein the RPSA gene is derived from a pig, and the RPSA sequence is as shown in NO.
1.
3. A method for constructing a ST cell line stably overexpressing RPSA according to claim 1 or 2, characterized in that the carboxyl end of the RPSA sequence contains a Flag tag protein.
4. The method for constructing a ST cell line stably overexpressing RPSA according to claim 1, wherein the cell line used is ST cell.
5. The method for constructing a ST cell line stably overexpressing RPSA according to claim 1, characterized in that: The vector used for the recombinant plasmid was pIRES.
6. A method for constructing a ST cell line stably overexpressing RPSA according to claim 1, 2 or 5, characterized in that: Before recombining the plasmid, the RPSA sequence is amplified. The forward primer and reverse primer sequences for amplifying the RPSA sequence are shown as No. 2 and No. 3, respectively.
7. The use of a ST cell line stably overexpressing RPSA according to any one of claims 1 to 6, characterized in that: Including its use in the production of pseudorabies vaccines.
8. The use of a ST cell line stably overexpressing RPSA according to claim 7, characterized in that: The constructed ST cell line that stably overexpresses RPSA is used for PRV virus amplification, which can increase the PRV virus titer and thus increase vaccine production.
